ES2112329T3 - Composiciones de vanadio. - Google Patents

Composiciones de vanadio.

Info

Publication number
ES2112329T3
ES2112329T3 ES92920526T ES92920526T ES2112329T3 ES 2112329 T3 ES2112329 T3 ES 2112329T3 ES 92920526 T ES92920526 T ES 92920526T ES 92920526 T ES92920526 T ES 92920526T ES 2112329 T3 ES2112329 T3 ES 2112329T3
Authority
ES
Spain
Prior art keywords
compositions
vanadium
vanadium compositions
oxovanadium
monoprotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92920526T
Other languages
English (en)
Inventor
John Hugh Mcneill
Hamid Reza Hoveyda
Chris Orvig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of ES2112329T3 publication Critical patent/ES2112329T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PROPORCIONAN COMPOSICIONES DE VANADIO PARA USO EN EL TRATAMIENTO DE HIPERTENSION, OBESIDAD Y DIABETES, EN PARTICULAR COMPOSICIONES ORALES MEJORADAS QUE COMPRENDEN QUELATOS DE OXOVANADIO (IV) DE OXIGENO BIDENTADO MONOPROTICO QUE COORDINA LIGANTES, ESPECIALMENTE ACIDO KOJICO Y MALTOL.
ES92920526T 1991-09-30 1992-09-29 Composiciones de vanadio. Expired - Lifetime ES2112329T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/767,510 US5300496A (en) 1991-09-30 1991-09-30 Complexed vanadium for the treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
ES2112329T3 true ES2112329T3 (es) 1998-04-01

Family

ID=25079727

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92920526T Expired - Lifetime ES2112329T3 (es) 1991-09-30 1992-09-29 Composiciones de vanadio.

Country Status (13)

Country Link
US (1) US5300496A (es)
EP (2) EP0811380A3 (es)
JP (1) JP3515107B2 (es)
AT (1) ATE162716T1 (es)
AU (1) AU2649792A (es)
CA (1) CA2120338A1 (es)
DE (1) DE69224293T2 (es)
DK (1) DK0606318T3 (es)
ES (1) ES2112329T3 (es)
GR (1) GR3026654T3 (es)
NZ (1) NZ244569A (es)
WO (1) WO1993006811A2 (es)
ZA (1) ZA927522B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527790A (en) * 1991-09-30 1996-06-18 The University Of British Columbia Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar
US5866563A (en) * 1991-09-30 1999-02-02 The University Of British Columbia Vanadium compositions
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
US5871779A (en) * 1994-01-18 1999-02-16 Mount Sinai Hospital Corporation Treatment of arthropathies with vanadate compounds or analogues thereof
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
GB9416767D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
US5863519A (en) * 1994-08-18 1999-01-26 Nycomed Imaging As Composition and method of MRI using both a positive and a negative contrast agent
WO1996005867A2 (en) * 1994-08-18 1996-02-29 Nycomed Imaging A/S Compositions
GB9416768D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
US5547685A (en) * 1995-05-16 1996-08-20 Eli Lilly And Company Methods for inhibiting bone loss with vanadyl sulfate
US5545661A (en) * 1995-05-16 1996-08-13 Eli Lilly And Company Methods for inhibiting bone loss with bis-pyrone oxovanadium compounds
US5885980A (en) * 1996-06-25 1999-03-23 Enrique G. Gutierrez Composition and method for treating diabetes
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US6232340B1 (en) 1997-04-24 2001-05-15 Angiotech Pharmaceuticals, Inc. Vanadium complexes and derivatives thereof and methods related thereto
EP0984971A1 (en) * 1997-04-24 2000-03-15 Angiotech Pharmaceuticals, Inc. Vanadium complexes and derivatives thereof and methods related thereto
US6245808B1 (en) * 1998-11-05 2001-06-12 Parker Hughes Institute Oxy-vanadium (IV) complexes having spermicidal activity
US6432941B1 (en) 1998-01-20 2002-08-13 Parker Hughes Institute Vanadium compounds for treating cancer
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
WO2000015211A2 (en) 1998-09-17 2000-03-23 Akesis Pharmaceuticals, Inc. Compositions of chromium or vanadium with antidiabetics for glucose metabolism disorders
US6287586B1 (en) 1998-09-18 2001-09-11 The University Of British Columbia Pharmaceutical compositions of vanadium biguanide complexes and their use
WO2000024730A1 (en) 1998-10-28 2000-05-04 The University Of British Columbia Organic vanadium(iii) complexes and their use
GB2396106B (en) * 2002-12-12 2006-11-15 Johnson & Johnson Medical Ltd Wound dressings comprising enzyme inhibitors
AU2005259231A1 (en) * 2004-07-02 2006-01-12 Genmedica Therapeutics Sl Arylalkylamine vanadium (V) salts for the treatment and/or prevention of diabetes mellitus
US20060165814A1 (en) * 2004-12-16 2006-07-27 Genmedica Therapeutics Sl Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia
US20070066682A1 (en) * 2005-07-01 2007-03-22 Exposito Miriam R Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus
US20080070987A1 (en) * 2006-05-12 2008-03-20 Francesc Yraola Font Meta-xylylenediamine vanadate salts
AU2012226703A1 (en) 2011-03-07 2013-10-17 Cfm Pharma Holding Bv Use of vanadium compounds for maintaining normaglycemia in a mammal
WO2012131689A1 (en) 2011-03-25 2012-10-04 Chaudhuri Mihir K Insulin mimetic active comprising oxodiperoxo vanadates and a pharamaceutical composition obtained thereof
JP7349052B2 (ja) * 2019-06-24 2023-09-22 湖南方升泰医薬科技有限公司 金属錯体の新規応用
CN111035652B (zh) * 2020-01-08 2021-08-24 辽宁大学 钒酸盐酪蛋白复合物在制备降糖药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1277599C (en) * 1986-10-16 1990-12-11 Barry I. Posner Vanadium - peroxide compositions as insulin mimickers
FR2619382B1 (fr) * 1987-08-11 1990-05-04 Lazaro Rene Compose organo-mineral de vanadyle, procede d'obtention d'un tel compose, composition pharmaceutique contenant ce compose organo-mineral
JPH02292217A (ja) * 1989-05-08 1990-12-03 Otsuka Pharmaceut Co Ltd 糖尿病治療薬

Also Published As

Publication number Publication date
AU2649792A (en) 1993-05-03
CA2120338A1 (en) 1993-04-15
DE69224293D1 (de) 1998-03-05
JPH06511244A (ja) 1994-12-15
EP0606318A1 (en) 1994-07-20
GR3026654T3 (en) 1998-07-31
EP0811380A2 (en) 1997-12-10
EP0811380A3 (en) 1999-01-20
WO1993006811A2 (en) 1993-04-15
ZA927522B (en) 1993-06-16
DK0606318T3 (da) 1998-09-23
US5300496A (en) 1994-04-05
NZ244569A (en) 1995-04-27
JP3515107B2 (ja) 2004-04-05
EP0606318B1 (en) 1998-01-28
ATE162716T1 (de) 1998-02-15
WO1993006811A3 (en) 1993-06-24
DE69224293T2 (de) 1998-07-09

Similar Documents

Publication Publication Date Title
ES2112329T3 (es) Composiciones de vanadio.
AP2000001929A0 (en) Substituted indolealkanoic acids.
DE69313284D1 (de) Verfahren zur deliquifizierung und zum bleichen von einem ligenocellulosischen material
MY129973A (en) Sulphonylbenzyl-substituted pyridones.
NO941770L (no) Substituert mono- og bipyridylmetylpyridon
DE60028376D1 (de) Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses
AU3245489A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
DE69703228T2 (de) Neue 6-Hydroxy und 6-Oxo-Androstan Verbindungen mit Kardioaktivität und pharmazeutische Präparate davon
DK1057826T3 (da) Substituerede dimere carboxamidforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DE69122282D1 (de) Komplexe und Chelate des Azithromycins als Antiulcus-Mittel
GEP20032914B (en) Derivatives of 1,3,4-Oxadiazolone
DE3575554D1 (de) Aminosaeurederivate mit antitumoraktivitaet sowie diese derivate enthaltende zusammensetzungen.
DK0977582T3 (da) Farmaceutiske kombinationspræparater, der indeholder erythropoietin og jernpræparater
EP0202673A3 (en) Titanocene complexes having a cytostatic activity
DK0684259T3 (da) L-Lysyl-glycyl-L-histidin og terapeutiske præparater med indhold deraf til sårheling
TR200001745T2 (tr) Keton peroksit türevleri, bunların hazırlanması ve kullanılması
ATE196909T1 (de) Polymerisationskatalysatoren
DK0688786T3 (da) Hydrazino- og hydroxyamino-14beta-hydroxyandrostanderivater med aktivitet på det cardiovaskulære system, fremgangsmåder til deres fremstilling og farmaceutiske præparater indeholdende disse.
IL89654A (en) Pharmaceutical combination compositions for treating hypertension
DE3160552D1 (en) Medicine containing a biflavanone compound
GB1525844A (en) 2-carbamoyl-1,2,4,5-tetrahydro-3h-2-benzazepin-3-ones

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 606318

Country of ref document: ES